The company provides services to pharmaceutical companies that use artificial intelligence to discover and identify antibodies. The company in its press release said that antibodies have shown a lot of promise as a candidate for targeted therapy as they bind specifically to their targets. The company said that its platform of AI-powered software has the potential to improve efficiency of the current methods and reduce antibody discovery process time and cost by more than 50%. ImmunitoAI was founded in November last year by Aridni Shah and Trisha Chatterjee.